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Background: Cardiac surgery has been shown to result in a significant decrease of the antioxidant selenium, which
is associated with the development of multiorgan dysfunction and increased mortality. Thus, a large-scale study is
needed to investigate the effect of perioperative selenium supplementation on the occurrence of postoperative
organ dysfunction.
Methods/Design: We plan a prospective, randomized double-blind, multicenter controlled trial, which will be
conducted in North and South America and in Europe. In this trial we will include 1,400 high-risk patients, who are
most likely to benefit from selenium supplementation. This includes patients scheduled for non-emergent combined
and/or complex procedures, or with a predicted operative mortality of ≥5% according to the EuroSCORE II.
Eligible patients will be randomly assigned to either the treatment group (bolus infusion of 2,000 μg sodium
selenite immediately prior to surgery, followed by an additional dosage of 2,000 μg at ICU admission, and a
further daily supplementation of 1,000 μg up to 10 days or ICU discharge) or to the control group (placebo
administration at the same time points).
The primary endpoint of this study is a composite of ‘persistent organ dysfunction’ (POD) and/or death within
30 days from surgery (POD + death). POD is defined as any need for life-sustaining therapies (mechanical ventilation,
vasopressor therapy, mechanical circulatory support, continuous renal replacement therapy, or new intermittent
hemodialysis) at any time within 30 days from surgery.
Discussion: The SUSTAIN-CSX™ study is a multicenter trial to investigate the effect of a perioperative high dosage
sodium selenite supplementation in high-risk cardiac surgical patients.
Trial registration: This trial was registered at Clinicaltrials.gov (identifier: NCT02002247) on 28 November 2013.
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Cardiac surgery is performed annually in approximately
one million patients worldwide. If current healthcare use
and service delivery patterns continue the demand for
cardiac surgery is expected to increase on the basis of
population growth and ageing [1].
Patients undergoing cardiac surgery with cardiopulmo-
nary bypass (CPB) are exposed to various ischaemic stimuli,
resulting from global ischaemic cardioplegic arrest of the
heart and/or from embolic events. Cessation of CPB and
reperfusion of ischemic vascular beds evokes oxidative
stress and triggers an intense inflammatory response, which
is associated with endothelial dysfunction, microvascular
thrombosis, immune dysfunction, and eventually the poten-
tial for injury of virtually all vital organs, including heart,
lungs, brain, kidneys and intestines (Figure 1) [2,3]. In
mammals, a sophisticated endogenous defense system pro-
tects tissues from oxidative stress. Several enzymes such as
catalase, superoxide dismutase and glutathione peroxidase
(GPx) are specifically designed to neutralize reactive oxygen
species [4]. For these antioxidant (AOX) enzymes, interestFigure 1 Multiple stimulus and treatment approaches in cardiac surger
from Hall [2]. CPB = cardiopulmonary bypass; IL = interleukin; TNF = tumor necin the essential trace elements selenium has arisen as it is
involved in multiple steps of intracellular AOX defense
[5,6] and thus can neutralize both reactive oxygen and ni-
trogen species [4]. Selenium is considered as the corner-
stone of the antioxidant defense mechanism and may be
one of the most important antioxidants [7]. When incorpo-
rated into the various selenoenzymes, selenium increases
its antioxidant capacity and influences the inflammatory
signaling pathways that modulate reactive oxygen species
(ROS) by inhibiting the nuclear factor-kappa b (NF-kB)
cascade, resulting in a suppressed production of inter-
leukins and tumor necrosis factor alpha (TNFα) [8].
In addition to critically ill patients, a significant selen-
ium deficiency and hence an insufficient endogenous anti-
oxidant capacity was recently demonstrated among patients
after cardiac surgery. Selenium levels fell with increasing
CPB time and continued to decrease postoperatively, when
compared to selenium levels from a healthy population not
undergoing surgery. Importantly, low selenium levels were
associated with postoperative complications and the intra-
operative selenium decrease showed a predictive accuracyy. The present figure was modified and reproduced with permission
rosis factor; PAI = Plasminogen activator inhibitor; NAC =N-acetylcysteine.
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Given those findings and recent results from a non-
randomized open-label study which indicated a beneficial
effect of perioperative sodium selenite supplementation
[11], we aim to study a perioperative sodium selenite sup-
plementation in a large-scale randomized trial, targeting
patients who have a high risk of pronounced selenium defi-
ciency. We hypothesize that the therapeutic strategy in this
randomized trial may contribute to a lower rate of organ




This is a randomized, double-blind (patients and phys-
ician), placebo controlled multicenter study, which will
be conducted in North America (Canada and United
States) and Europe (Belgium, Switzerland and Germany),
with an aim to enroll approximately 1,400 patients to
evaluate the overall study hypothesis.
Ethics
The present study (study protocol, patient information
and informed consent) is approved by the ethics commit-
tee of RWTH Aachen University (Ethik-Kommission an
der Medizinischen Fakultät der RWTH Aachen, ethic vote
EK 249/13) and Queens University (Kingston, Canada).
Furthermore it has been approved by Health Canada and
the Bundesinstitut für Arzneimittel und Medizinprodukte
(BfArM) in Germany. Written informed consent from the
patient and treating anesthesiologist or surgeon will be
obtained before enrolment in the study.
Inclusion criteria
Participants in the trial must be adult patients (>18 years
of age) scheduled to undergo elective cardiac surgery with
the use of cardiopulmonary bypass (CPB) and cardioplegic
arrest that exhibit a high perioperative risk profile as
defined by either: 1.) planned valve surgery combined with
coronary artery bypass grafting or 2.) multiple valve re-
placement and/or repair surgeries or 3.) combined cardiac
surgical procedures involving the thoracic aorta or 4.)
scheduled cardiac surgery with a high perioperative risk
profile, defined as a predicted operative mortality of ≥5%
(EuroSCORE II).
These high-risk patients have recently been shown to ex-
perience an excessive systemic inflammatory response, with
the most pronounced decrease of selenium during surgery
[10,12]. Furthermore it has been demonstrated that post-
operative selenium blood levels were inversely correlated
with duration of CPB. More precisely, the longer the surgi-
cal procedure, the more pronounced the postoperative
decrease in circulating selenium levels (r = −0.121, P <0.05)
[9]. In addition, the results of our collaborators and thosefrom a recently published study revealed that the pre-
operatively assessed EuroSCORE I inversely correlated to
the postoperatively measured selenium levels (r = −0.312,
P <0.01), indicating that this group would be most likely
to benefit from perioperative selenium supplementation
[9]. These same criteria enabled the identification of
patients who were likely to experience a prolonged ICU
course [13], which will offer some statistical efficiencies
given the higher rate of organ dysfunction and need for
prolonged administration of life-sustaining therapies.
Since previous randomized trials in cardiac surgery
often lacked generalizability, particularly in the case of
elderly patients, we decided to enroll patients in accor-
dance to the recommendations of the American Heart
Association Council on Clinical Cardiology without any
age restriction [14].
Exclusion criteria
We will exclude patients who meet any of the following
criteria: 1) known hypersensitivity to sodium selenite or
to any of the constituents of the solution, 2) severe renal
dysfunction as evidenced by preoperative creatinine clea-
rance <50 ml/min and/or preoperative value of serum
creatinine level >200 μmol/L, 3) chronic liver disease as
evidenced by a preoperative total bilirubin >2 mg/dl or 34
umol/L, 4) disabling neuropsychiatric disorders (severe
dementia, severe Alzheimer’s disease, advanced Parkinson’s
disease), 5) pregnancy or lactation period, 6.) simultaneous
participation in another clinical trial of an experimental
therapy (co-enrolment acceptable in observational studies
or randomized trials of existing therapies if permitted by
both steering committees and local ethics boards), 7)
patients undergoing heart transplantation or preoperative
planned LVAD insertion or complex congenital heart
surgery.
These exclusion criteria will enable us to exclude pa-
tients who have the lowest likelihood of deriving benefit
from the study intervention, and those at high risk of
having an atypical postoperative course (patients under-
going heart transplantation), and thus potentially inter-
fering with the valid determination of our primary endpoint.
Random allocation of patients
At each participating centre the local coordinating inves-
tigator will screen daily all cardiac surgical patients
scheduled to undergo cardiac surgery in the near future
or on the next day. A screening log will be kept at each
site to determine the number of patients meeting the in-
clusion criteria, those truly eligible patients, those who
consent and are randomized, and reasons why poten-
tially eligible patients were not enrolled. Following a full
explanation of the nature and purpose of the study, writ-
ten informed consent will be sought from the patients
participating in the study. At the time of enrolment into
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dium selenite or a matching placebo similar in appearance,
consistency, volume, and smell so as to blind patients,
investigators and healthcare practitioners as to the nature
of the study medication. Patients will be consecutively ran-
domized by a web-based randomization system (concealed
and blinded) developed by the Clinical Evaluation Research
Unit at the Kingston General Hospital and will be based on
the method of permutated blocks of undisclosed random
size and stratified by centre.
Intervention
Patients will receive daily perioperative treatment of either
high-dose sodium selenite or placebo. As with our previ-
ously referenced preliminary studies, all patients will re-
ceive an intravenous bolus of 2,000 μg sodium selenite
(equal to 40 ml prepared solution) or the same volume of
normal saline (placebo) within 30 minutes after induction
of anesthesia via the central venous catheter. This bolus
dose will be completed prior to commencing cardiopul-
monary bypass. After termination of surgery, immediately
after admission to the ICU, all patients will receive a sec-
ond bolus of 2,000 μg sodium selenite or placebo, accord-
ingly. This additional postoperative bolus is in response to
the postoperative drop in selenium levels observed on day
1 in a recently completed open label trial (Figure 2) [11].
This postoperative drop may be due to sustained oxidative
stress, bleeding or transfusions that frequently occur in
the first 24 hours of surgery in patients with prolonged
CPB. Then, on every subsequent morning (8:00 am)
during ICU stay, patients will receive a continuous infu-
sion of 1,000 μg sodium selenite or placebo overFigure 2 Perioperative time course of whole blood concentrations
of selenium. The shaded area indicates the reference range for whole
blood selenium concentration in Germany. BL: Baseline before induction
of anesthesia; AD: admission to the ICU; 4 hrs: 4 hours after admission to
ICU. *P <0.05 versus baseline. **P <0.01 versus baseline. This picture was
taken from [11]. The shaded area indicates the reference range. Data are
given as means ± SD.30 minutes via central or peripheral venous access. The
daily administration of study solution will continue until
death, discharge from ICU (or a step down/intermediate
care unit), or for a maximum of 10 days. This dosing regi-
men was chosen according to efficacy, tolerability and
safety that was confirmed in previous supplementation tri-
als in patients with systemic inflammation and cardiac
surgery [11,15,16]. The intervention drug and placebo so-
lution will be supplied by biosyn Arzneimittel GmBH
(Fellbach, Germany), an industry partner that manufac-
tures intravenous sodium selenite in accordance to good
manufacture practice (GMP) guidelines and will be pro-
vided in such a way as to maintain blinding. Since there
exist numerous treatments which may influence the study
outcome, we will attempt to guide and standardize at least
the management of anaesthesia, intensive and nutritional
support (please see Additional file 1).
Blinding and protection against bias
At the time of enrolment into the study, researchers will be
blinded to the treatment assignment (guarding against se-
lection bias). Patients will be randomized to receive either
sodium selenite or a matching placebo similar in appea-
rance (consistency, volume and smell) so as to blind pa-
tients, investigators and healthcare practitioners as to the
nature of the study medication (guarding against perfor-
mance and detection bias). Recording of relevant clinical
data and neurocognitive assessments, will be performed
by study personnel blinded to group allocation during the
ICU stay (well established CAM-ICU questionnaire,
which evaluates the acute onset or fluctuating course, in-
attention, altered level of consciousness, and disorganized
thinking [17]).
Consistent with the intention-to-treat principle, all ran-
domized patients will be included in the analysis. Large
numbers of patients lost to follow-up would threaten the
validity of this trial. Given that the study occurs in hospital
and the majority of the outcomes, including the primary
outcome, will be assessed in hospital, we anticipate no loss
to follow up in hospital and less than 10% for post-
discharge follow-up assessments. With respect to the
planned mid-term follow-up portion of the study (secon-
dary endpoint), to guard against attrition bias, we will take
the following proactive strategies shown to enhance reten-
tion: 1) we will obtain the contact information of a family
member in case we cannot contact the patient and/or if
the patient is not able to provide information, to obtain
the most important patient-centered physical function on
SF-36 from the family member [18]; 2) the study coordin-
ator will contact the patient and family member at the
time of ICU discharge to build a relationship and reinforce
the need for subsequent contact (after three and six
months); 3) respondents will be notified of upcoming in-
terviews by means of mail-out reminders; and 4) we will
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public registries.
The monitoring of sites will be performed by the CERU
at the Kingston General Hospital, Ontario, Canada (for
the Canadian sites) and by the Clinical Trial Center
(CTC) Aachen at RWTH Aachen University, Germany.
Endpoints
Primary outcome
The primary objective of the definitive trial is to investigate
the effect of a high-dose sodium selenite perioperative sup-
plementation on clinical outcomes in cardiac surgical pa-
tients at high risk for perioperative complications. The
selection of a primary clinical outcome for large-scale trials
in cardiac surgery is associated with a number of chal-
lenges. Options include mortality, length of stay in the ICU
and various composite endpoints. Mortality rates are too
low in this population to be a responsive primary outcome
for this intervention. At the Ottawa Heart Institute, over
the past five years in-hospital mortality rate for all patients
(elective and emergent) was 3.1%. A total sample size of
over 22,000 patients would be required to achieve 80%
power to detect a 20% relative risk reduction (RRR) to
2.5% at a two-sided alpha = 0.05. Furthermore, focusing on
mortality alone misses the beneficial (or adverse) effect of
treatments on morbidity and quality of life. Length of stay
in an ICU may be a potential outcome but discharge prac-
tices are tremendously variable across units, and are
dependent on non-clinical factors such as availability of
beds, rendering this outcome less sensitive to detect a
treatment effect. A standard composite endpoint of all-
cause mortality, myocardial infarction, stroke, renal failure,
and prolonged mechanical ventilation could be considered
but the inclusion of stroke, particularly due to embolic ori-
gins, would not be expected to be modified by our pro-
posed treatment strategy. Moreover, combining myocardial
infarction defined by a biochemical change (troponin rise)
with an event such as death challenges the validity of the
composite endpoint.
A fourth option could be to use persistent organ dysfunc-
tion (POD) + death as a composite endpoint. POD is de-
fined as the need for life-sustaining therapies at any time
postoperatively (life-sustaining therapy, mechanical ventila-
tion (includes non-invasive ventilation), any vasopressor
therapy, mechanical circulatory support, continuous renal
replacement therapy or intermittent hemodialysis). The pri-
mary endpoint will be the number of days alive and POD-
free, which will be evaluated by the composite outcome
POD+ death within the first 30 days after surgery.
We have validated this endpoint in critically ill pa-
tients before and have shown that patients who develop
POD are at higher risk for subsequent death and long-
term disability or lower quality of life compared to those
who do not have POD [19]. In a similar study of cardiacsurgery patients, Williams et al. showed that the persist-
ence of multiple organ failure identifies a subpopulation
of surgical patients that have a high likelihood for death
or poor physical function over the subsequent two years
[20]. Moreover, given our biological model illustrated in
Figure 1, POD would be the most direct outcome and
the most sensitive to detecting a treatment effect of so-
dium selenite (Figure 1).
The 30-day time frame is commonly used in the car-
diac surgery literature because there is virtually no loss
to follow-up during this period and there are only about
5% of outlying patients who remain alive and dependent
on life-sustaining therapy after (sometimes months after)
30 days. Patients who die within 30 days will be given a
value of 0 free days. This outcome will have properties
similar to ‘ventilator free days’ which has been widely ac-
cepted in critical care medicine and used in several recent
major RCTs [21-23]. Free days will only be counted if they
persist for at least 48 hours prior to re-application of life
sustaining therapy and are not followed by death within
30 days. We propose to compare the primary outcome be-
tween arms using the Wilcoxon rank sum test. The daily
proportion of patients alive and free of life-sustaining ther-
apy by arm over the first 30 days will be depicted graphi-
cally. The primary analysis will follow the intent-to-treat
principle, including all patients in the arm they were ran-
domized to regardless of treatment compliance. The ana-
lysis and study reporting will be in accordance with the
CONSORT statement [24].
Secondary outcomes
Secondary outcomes for the larger scale trial will include
perioperative hemodynamic profile (for example mean ar-
terial blood pressure, cardiac output, systemic vascular re-
sistance and so on), cardiovascular complications (such as
arrhythmias, cardiac arrest and infarction), ventilator free
days, the occurrence of postoperative delirium (assessed
by CAM-ICU score) over time, length of stay in the ICU
and hospital, re-admission rates, hospital-acquired infec-
tions (proven bacteremia) and 30-day mortality. We plan
to follow study patients prospectively during the ICU stay,
documenting the compliance with the study procedure,
reasons for interruptions of study medications and pri-
mary and secondary outcomes. Additionally, we will con-
tact patients by telephone at three and six months to
assess survival and health-related quality of life (using SF-
36 scores) as in our previous antioxidant trial of critically
ill patients [25].
Besides these clinical data, we plan to obtain an exten-
sive pharmacokinetic and pharmacodynamic evaluation
of our sodium selenite supplementation regimen. Blood
samples will be drawn prior to surgery (pre-treatment),
after surgery (ICU admission), at the first postoperative
day (before start of selenium application) and then daily
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mine whole blood selenium levels (measured by atomic
absorption spectroscopy to ensure determination of sel-
enium independent from the compartment). In addition,
incorporation of selenium into selenoproteins will be mea-
sured through monitoring of GPx activity and selenopro-
tein P (Sel-P) levels, both of which have been repeatedly
shown to correlate with the circulating selenium levels
[26,27]. In addition, we aim to perform genotyping ana-
lysis to evaluate the effects of genotype on metabolism,
selenium status and health outcomes. The relative ratio
between two isoforms of Sel-P has been reported to be in-
fluenced by genotype with respect to two single nucleotide
polymorphisms (SNPs) in the Sel-P gene, the effect of
which was abrogated under conditions of selenium sup-
plementation [27]. Since Sel-P is crucially involved in the
systemic selenium transport (blood and tissue), we thus
aim to evaluate the significance of the underlying geno-
type on patients’ response to supplementation and pa-
tients’ outcome after surgery. Furthermore, we hope to
reveal new insights into the underlying genotype with re-
spect to further selenoproteins.
We shall also aim to assess the extent of oxidative
stress and inflammation by measuring MDA-LDL IgM
(antibodies against oxidized LDL), asymmetric dimethyl-
arginine (ADMA), endogenous peroxidase activity (EPA)
and the well-established markers of inflammation: inter-
leukin (IL)-6, IL-10 and TNFα in a substudy. All col-
lected blood samples will be stored at −80°C until final
analysis in a central lab at Aachen University. Standard
lab tests to detect myocardial ischemia (to detect tropo-
nin, for example), inflammation (C-reactive protein) and
organ function (creatinine, urea, arterial blood gases,
bilirubin and hemoglobin) will be performed according
to clinical routine and as clinically indicated.
Statistical analysis
Justification of sample size for the definitive trial
From a database of all patients that underwent cardiac
surgery between 1 January 2011 and 31 December 2011 at
the University Hospital of Aachen, Germany (n = 1127)
and met present inclusion criteria (n = 170), we estimated
the control arm distribution of POD free days. In this
dataset the mean (SD) POD free days was 23.2 (9.2), fac-
toring in a mortality rate of 4%. The distribution and cu-
mulative distribution of POD free days shows that 4% of
the patients died, 6% survived but had 0 POD free days
and 58% had 26 to 29 free days. Only 15% of patients had
between 1 and 20 free days. These numbers are consistent
with the 4% 30-day mortality rate and the 6% not yet free
from life-sustaining therapy by 30 days that we observed
from the 83 patients seen at the University of Ottawa
Heart Institute between July 2012 and June 2013 who met
the eligibility criteria of the current calculation. Similar toventilator free days, the distribution of free days is
clearly not Gaussian, with most of its distribution near
the minimum and maximum possible values of 0 and
30 respectively.
We performed simulation in order to accurately esti-
mate the actual power of applying the Wilcoxon rank-
sum test to scenarios with various effect sizes where the
control arm had the same distribution as observed from
our German data. The simulation generated data in the
control arm where the mortality rate was 4% and the
daily rate (hazard) of being liberated from life-sustaining
therapy was the same as observed within our German
data. The intervention arm was then generated by multi-
plying the control arm daily rate of liberation by a fixed
factor (hazard ratio). The mean days on life-sustaining
therapy was then subtracted from 30 to obtain the free
days. All estimates are based on simulating 10,000 sam-
ples of the required sample size, so power estimates will
have more than a 95% chance of being accurate to within
1%. It derived from a virtual calculation, which showed
that the distribution of the simulated control arm was
nearly identical to the distribution of the actual observed
German data. The calculation also provided the distribu-
tion of the intervention arm when the intervention causes
a 20% relative increase in the daily rate of liberation from
life-sustaining therapy compared to the control arm.
We expect that the sample size of the definitive trial
will be approximately 700 per arm. This would provide
about 90% power to detect a 20% relative increase in the
daily rate of liberation from life-sustaining therapy. Such
an effect size would result in a mean decrease of 1.5 days
in the days of life-sustaining therapy from 6.8 to 5.3 days,
or equivalently, a 1.5 day increase from 23.2 to 24.7 free
days. We believe such an effect size is plausible and is in
line with minimally clinically important differences ac-
cepted in other recent major trials in the ICU setting.
Pilot study
Before advancing to a large-scale trial, a randomized,
double-blind, placebo controlled pilot study of 80 pa-
tients will be carried out to determine the feasibility of a
multicenter RCT, uncover problems regarding recruit-
ment of patients, adherence with the study protocol and
any contaminations (such as the co-application of selen-
ium) and to develop study procedures for a large-scale
RCT. The primary focus of the pilot study thus is to evalu-
ate: 1) Recruitment of trial patients. Successful recruitment
will be defined as >2 patients per month per site on aver-
age. A recruitment of 2 to 3 patients per month is consid-
ered as reasonable given the high numbers of competing
studies in the field of cardiac surgery, missed patients and
consent failure rates, all of which might limit our ability to
enroll all of these potentially eligible patients. We expect to
monitor success with recruitment throughout the study
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gibility criteria as necessary. 2.) Adherence to protocol.
Successful adherence will be defined as ≥90% of prescribed
intervention being administered across all patients. Prelim-
inary estimates of non-administration of the trial interven-
tion are needed, along with experience with behavioral
strategies that maximize exposure to the intervention. 3.)
Contamination. Success will be defined if <5% of patients
have any non-study open-label intravenous selenium, in
either group, during their hospital stay. Intravenous sel-
enium is not currently the standard of care in any par-
ticipating center but this outcome is important because
contamination introduces risk of bias. A careful evalu-
ation of the threat of contamination is key and mitigat-
ing strategies need to be identified.
After completion of this pilot trial, we will initiate the
definitive randomized, double-blind, placebo controlled
multicenter trial to evaluate our overall study hypothesis.
Sites participating in the Canadian component of the
multinational, multicenter pilot study include: University
of Ottawa Heart Institute, Montreal Heart Institute and
Sunnybrook Health Sciences Center. In addition, three
European centers (RWTH Aachen University, Germany,
University Hospital Frankfurt, Germany and Kiel University,
Germany) will also be implementing the pilot study at
their respective institutions. An additional objective of the
pilot study is to finalize the primary outcome for the
large-scale trial and develop estimates that can be used for
a more precise calculation of the sample size for a large-
scale trial. While a data safety monitoring committee has
not yet been established for the pilot trial, it will be imple-
mented for the definitive trial.
After completion of this pilot phase, descriptive and infer-
ential statistics (mostly rates with 95% confidence intervals)
will be presented to describe the pilot study feasibility out-
comes. Safety and pharmacokinetic variables will be de-
scribed by arm. However, due to the limited sample size
and the potential of rolling the pilot study into the defini-
tive study, clinical efficacy outcomes will be reported overall
but not by arm. There are no planned interim or subgroup
analyses for this pilot trial.
Discussion
A significant number of patients require cardiac surgery
for the management of their underlying heart disease. In
addition to death, major morbidity from organ failure re-
mains frequent following cardiac surgery, particularly in
patients at high risk for complications and poor clinical
outcomes. The perioperative inflammatory response as it
occurs during the process in cardiac surgery is considered a
major contributor to surgery-associated complications [3].
Various studies have previously demonstrated the cru-
cial role of the essential trace element selenium within the
multiples steps of antioxidant defense [8], and circulatingselenium levels have been shown to correlate with the
activity of GPx and other selenoenzymes in different
clinical settings. In addition, selenium affects both the
cell-mediated and the humoral immune defense mecha-
nisms, and depressed selenium levels are associated
with the reduction of natural killer cells [28,29]. Inte-
restingly the administration of sodium selenite is postu-
lated to have a biphasic action, initially as a pro-oxidant
and then as an antioxidant [30]. The early transient pro-
oxidant effect of selenite might be a useful therapeutic
strategy. In fact, an intravenous loading dose given as a
bolus could have the following effects: 1) direct reversible
inhibition of NF-κB binding to DNA controlling gene ex-
pression and thus downregulation of the synthesis of pro-
inflammatory cytokines [31], 2) induction of apoptosis
and cytotoxicity at the microcirculation level [32], and 3) a
direct virucidal and bactericidal effect [30]. Wang et al.
[33] demonstrated that a selenite loading bolus causes a
transient peak plasma concentration of selenium and bene-
ficial improvements in hemodynamics status, proinflamma-
tory cytokines profile and survival. However, these findings
have never been proven in ICU patients where plasma sel-
enium significantly decreases [34].
In view of an impressive body of evidence that indicates
a beneficial role of sodium selenite during inflammation,
various preliminary clinical trials attempted to enhance the
antioxidant and immunological defense mechanisms in
critically ill patients by a sodium selenite supplementation
strategy [15,16,35-38]. Accordingly, results from a recent
meta-analysis indicated a significantly reduced incidence of
infections and mortality in critically ill patients who had re-
ceived a high dose (>500 μg) selenium supplementation
during their ICU stay [28]. In the same way, Alhazzani et
al. [39] and Huang et al. [40] very recently demonstrated
reduced mortality in critically ill patients after selenium
supplementation. While there is good evidence of benefit
from selenium supplementation in critical illness, the opti-
mal timing and dosage of selenium supplementation re-
mains unclear.
A cardiac surgical setting with myocardial ischemia and
reperfusion seems to be an ideal model to investigate the
effect of perioperative sodium selenite supplementation.
Indeed, two recently published studies investigated the ef-
fect of a perioperative sodium selenite supplementation in
cardiac surgical patients. In a randomized trial, 117 pa-
tients received preoperative metabolic therapy, which con-
sisted of several antioxidants (coenzyme Q10, magnesium,
lipoic acid, omega-3 fatty acids and sodium selenite) and
was compared to a placebo. In this study, the application
of a metabolic cocktail resulted in reduced oxidative stress,
less myocardial injury and reduced length of hospital stay
[41]. In addition, results from a recently published open
label trial, investigating the safety and pharmacokinetics of
high-dose sodium selenite supplementation in cardiac
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were effective in preventing the intraoperative decrease
of circulating selenium levels. When comparing so-
dium selenite-treated patients with a historical control
group of cardiac surgical patients, the treatment group
had less organ dysfunction, as assessed by the Sequential
Organ Failure Assessment (SOFA) score on the first post-
operative day. However, the loading dose was apparently
not high enough to prevent the fall in circulating selenium
levels to baseline levels on the first postoperative day. For
this reason, the supplementation strategy in the present
trial has been modified and a second loading dose of so-
dium selenite was added on admission to the ICU to com-
pensate for this.
Pharmacokinetic studies suggest that optimal incorpor-
ation of supplemental selenium into selenoproteins requires
approximately 72 hours [29], and there is some evidence to
suggest that post-injury normalization of selenium levels is
unable to significantly affect the incurred oxidative damage
[42]. In this regard, we did consider including a preopera-
tive oral sodium selenite supplementation in addition to
our intravenous perioperative supplementation as part of a
2 × 2 factorial design. However, most participating cardiac
centers report a high volatility in surgical booking and sub-
sequent cancellation and re-scheduling (for example at
University of Ottawa Heart Institute over a recent six
month period 80% of the original elective and/or in-
hospital urgent bookings were rescheduled from their ori-
ginal booked date (BM, personal communication)). Thus,
it appeared highly likely that there would be major issues
surrounding compliance and variability of any preopera-
tive supplementation intervention, which would impact
greatly on such a trial. In the current proposed pilot trial
we will track timing and occurrences of screening, book-
ing, cancellation and surgical dates to determine if and
how a preoperative supplementation strategy might be
feasible in a definitive trial.
In the present trial only high-risk cardiac surgical pa-
tients will be included. Previous data indicate that these
patients are exposed to the most pronounced decrease
of selenium during surgery [10], leading to the develop-
ment of various organ dysfunctions. In addition, previ-
ous studies indicated that postoperative selenium blood
levels were inversely correlated with duration of CPB,
that is, the longer the surgical procedure, the more pro-
nounced the postoperative decrease in circulating selen-
ium levels [9,10]. In addition, it was demonstrated that
the preoperatively assessed EuroSCORE I inversely cor-
related to the postoperatively measured selenium levels
(r = −0.312, P <0.01), indicating that this is the group of
people who are most likely to benefit from perioperative
selenium supplementation [9].
In conclusion, the SUSTAIN-CSX™-study is a prospective,
randomized, double-blind, multicenter controlled multinationaltrial to investigate the effect of perioperative high-dose so-
dium selenite supplementation on the persistence of organ
dysfunction in approximately 1,400 high-risk cardiac sur-
gical patients.
Trial status
Recruitment and enrollment of the first patients (pilot
study) in both countries will start end of August 2014.
Additional file
Additional file 1: Management of anesthesia and cardiopulmonary
bypass: recommendations for general anesthesia and management
of cardiopulmonary bypass in enrolled patients. Intensive care unit
and nutritional support: recommendations and rules for postoperative
management of enrolled patients during the ICU stay with respect to
extubation, discharge from ICU and nutrition.
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